Parkinsonian Disorders
|
0.500 |
AlteredExpression
|
group |
BEFREE |
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) exacerbates mitochondrial impairment and α-synuclein expression leading to Parkinsonism.
|
31732923 |
2020 |
Parkinsonian Disorders
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Parkinsonism-linked mutations in alanine and glutamic acid residues of the pre-synaptic protein α-Synuclein (α-Syn) affect specific tertiary interactions essential for stability of the native state and make it prone to more aggregation.
|
31385584 |
2019 |
Parkinsonian Disorders
|
0.500 |
Biomarker
|
group |
BEFREE |
Effects of Exercise and Ferulic Acid on Alpha Synuclein and Neuroprotective Heat Shock Protein 70 in An Experimental Model of Parkinsonism Disease.
|
30113007 |
2019 |
Parkinsonian Disorders
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Six α-synuclein (aSyn) point mutations are currently known to be associated with familial parkinsonism: A30P, E46K, H50Q, G51D, A53E, and A53T.
|
30605594 |
2019 |
Parkinsonian Disorders
|
0.500 |
Biomarker
|
group |
BEFREE |
We used a novel real-time quaking-induced conversion (RT-QuIC) assay to detect α-synuclein (α-syn) aggregates in cerebrospinal fluid (CSF) of 118 patients with parkinsonism of uncertain clinical etiology and 52 controls.
|
30801759 |
2019 |
Parkinsonian Disorders
|
0.500 |
Biomarker
|
group |
BEFREE |
PD is characterized by intraneuronal accumulation of abnormal α-synuclein in brainstem while neurodegenerative parkinsonisms might be associated with accumulation of either α-synuclein, as in the case of Multiple System Atrophy (MSA) or tau, as in the case of Corticobasal Degeneration (CBD) and Progressive Supranuclear Palsy (PSP), in other disease-specific brain regions.
|
31406572 |
2019 |
Parkinsonian Disorders
|
0.500 |
Biomarker
|
group |
BEFREE |
Ultrasensitive Detection of Aggregated α-Synuclein in Glial Cells, Human Cerebrospinal Fluid, and Brain Tissue Using the RT-QuIC Assay: New High-Throughput Neuroimmune Biomarker Assay for Parkinsonian Disorders.
|
30706414 |
2019 |
Parkinsonian Disorders
|
0.500 |
Biomarker
|
group |
BEFREE |
The aggregation of NFTs, the abnormal hyperphosphorylation of tau protein, and the interaction between tau and alpha-synuclein may all contribute to the cell death and poor axonal transport observed in PD and Parkinsonism.
|
30333786 |
2018 |
Parkinsonian Disorders
|
0.500 |
Biomarker
|
group |
BEFREE |
The current study investigated the role of α-synuclein aggregation and UPS in Zn-induced Parkinsonism.
|
29198021 |
2018 |
Parkinsonian Disorders
|
0.500 |
AlteredExpression
|
group |
BEFREE |
<b>Results:</b> Plasma α-synuclein level was significantly increased in patients with PD and APS when compared with controls and FTD without parkinsonism (<i>p</i> < 0.01).
|
29755341 |
2018 |
Parkinsonian Disorders
|
0.500 |
Biomarker
|
group |
BEFREE |
We performed Sanger sequencing of all coding LRRK2 and SNCA exons in a sample of 91 patients with Parkinsonism.
|
29248340 |
2018 |
Parkinsonian Disorders
|
0.500 |
Biomarker
|
group |
BEFREE |
We used two different procedures, first, the adoptive transfer of splenocytes from αSyn/Grp94-immunized mice to recipient animals, and second, direct immunization with αSyn/Grp94, to study the effects in a chronic mouse MPTP-model of parkinsonism.
|
29024008 |
2018 |
Parkinsonian Disorders
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We screened for the p. A53T SNCA mutation a total of 347 cases of Greek origin with parkinsonism and/or dementia, collected over 15 years at the Neurogenetics Unit, Eginition Hospital, University of Athens.
|
29233723 |
2018 |
Parkinsonian Disorders
|
0.500 |
Biomarker
|
group |
BEFREE |
These data suggest that phosphorylated α-synuclein accumulates in the retina in parallel with that in the brain, including in early stages preceding development of clinical signs of parkinsonism or dementia.
|
29737566 |
2018 |
Parkinsonian Disorders
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Our study is the first to uncover the potential link between manganese exposure, altered miRNA expression and parkinsonism: manganese exposure causes overexpression of SNCA and FGF-20 by diminishing miR-7 and miR-433 levels.
|
28986288 |
2018 |
Parkinsonian Disorders
|
0.500 |
Biomarker
|
group |
BEFREE |
A Meta-Analysis of α-Synuclein Multiplication in Familial Parkinsonism.
|
30619023 |
2018 |
Parkinsonian Disorders
|
0.500 |
Biomarker
|
group |
BEFREE |
The operational definition requires clinical ascertainment of a levodopa-responsive parkinsonism with no "atypical" features, and pathological criteria based on the finding, usually at postmortem, of aggregates of α-synuclein in Lewy bodies and Lewy neurites.
|
30584155 |
2018 |
Parkinsonian Disorders
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Parkinsonism due to A53E α-synuclein gene mutation: Clinical, genetic, epigenetic, and biochemical features.
|
30423204 |
2018 |
Parkinsonian Disorders
|
0.500 |
Biomarker
|
group |
BEFREE |
It is now well established that LB-type α-synuclein aggregates also occur in the peripheral autonomic nervous system in PD, from where it has been speculated they may progressively spread to the central nervous system through synaptically-connected brain networks and reach the substantia nigra to trigger herein dopaminergic dysfunction/degeneration and subsequent parkinsonism.
|
29422109 |
2018 |
Parkinsonian Disorders
|
0.500 |
GeneticVariation
|
group |
BEFREE |
α-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism.
|
29310663 |
2018 |
Parkinsonian Disorders
|
0.500 |
Biomarker
|
group |
BEFREE |
Ample evidence has suggested that extracellular α-synuclein aggregates would play key roles in the pathogenesis and progression of Parkinsonian disorders (PDs).
|
28297586 |
2017 |
Parkinsonian Disorders
|
0.500 |
Biomarker
|
group |
BEFREE |
We included studies that reported data on CSF total, oligomeric and phosphorylated α-synuclein in patients with PD and healthy participants, neurological controls, or other parkinsonisms.
|
28880418 |
2017 |
Parkinsonian Disorders
|
0.500 |
Biomarker
|
group |
BEFREE |
We briefly discuss some of the lessons we have learned from research into the physiological role of α-synuclein and its pathological links to neurodegeneration and parkinsonism.
|
28324300 |
2017 |
Parkinsonian Disorders
|
0.500 |
Biomarker
|
group |
CTD_human |
Glucose Metabolism and AMPK Signaling Regulate Dopaminergic Cell Death Induced by Gene (α-Synuclein)-Environment (Paraquat) Interactions.
|
27324791 |
2017 |
Parkinsonian Disorders
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Disorders with progressive accumulation of α-synuclein (α-syn) are a common cause of dementia and parkinsonism in the aging population.
|
28476636 |
2017 |